Hofseth BioCare ASA (HBCO.XC)
| Previous close | 3.4000 |
| Open | 3.2600 |
| Bid | 3.1200 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 3.1200 - 3.3800 |
| 52-week range | 2.7000 - 3.3800 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.363B |
| Beta (5Y monthly) | 0.41 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3700 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Globe NewswireHofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY
Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into an agreement with HBC to distribute its science-led marine nutrition ingredients, ProGo® bioactive peptides, OmeGo® full spectrum omegas and CalGo® natural, undenatured type II collagen, to supplement manufacturers across the country. Lithy, which was established in 2002, has three subsidiaries that su
GlobeNewswireHofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT
The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17 % YoY. The underlying growth we are seeing is coming from both the ingredients business and finished products channels. The ingredients business continues to have solid demand growth especially for our core petfood products, and we have seen increased demand for our premium pure SPH product within this segment. We are also excited to have launched two new prod
- Globe Newswire
Hofseth Biocare ASA: Annual General Meeting completed
Hofseth BioCare ASA held its Annual General Meeting on 10 May 2024. 270,174,810 shares, amounting to 68.38 per cent of the share capital, were represent in the meeting or by proxy. All proposals were resolved as presented in the notice issued on 19 April 2024 and the recommendations from the Election committee. The minutes from the Annual General Meeting are attached. For further information, please contact: Jon Olav Ødegård, CEO at HBC Phone: +47 936 32 966 E-mail: joo@hofsethbiocare.no About H
